A Melanoma Prognostic Model Using Tissue Microarrays and Genetic Algorithms
Provided is a method for determining the risk that a patient diagnosed with melanoma will develop a recurrence of melanoma comprising: a) determining the level of expression for each marker of a panel of markers, wherein the panel comprises activating transcription factor 2, p21V1AF1, p16NK4A, beta-catenin, and fibronectin and the levels of expression are determined in compartments of interest in a tumor tissue sample from the patient; and b) determining whether an expression parameter for each marker in the tumor tissue sample is achieved by comparing the level of expression of each marker with a predetermined reference level associated with each marker; wherein the patient is at a low risk of developing a recurrence of melanoma if four or more of the expression parameters are achieved and is at a high risk of developing a recurrence of melanoma if three or fewer of the expression parameters are achieved.
RIMM DAVID L [US]; BERGER AARON J [US]; ROTHBERG BONNIE [US]; CAMP ROBERT L [US]; KLUGER HARRIET [US]
Type of Offer:
« More Genetics Patents